Abstract
Testosterone deficiency syndrome (TDS) induces several negative effects that generally involve different organs such as testis, bone, skeletal muscle, and heart, leading to reduction in testis function, causing osteoporosis, strongly reducing muscle mass, decreasing exercise capacity and strength and facilitating heart failure. Approximately 25% of patients affected by chronic heart failure (CHF) is characterized by plasma Testosterone (T) levels below normal ranges also related to disease progression. In addition, reduction of circulating testosterone levels may contribute to some specific features of CHF, such as abnormal energy handling, weakness, dyspnoea and cachexia in particular. According to some recent evidence it has emerged that testosterone replacement therapy (TRT) may improve muscle strength and functional pulmonary capacity in CHF men with TDS.
This review will place emphasis on the pathophysiological role of testosterone deficiency in CHF men as well as the effects of the testosterone replacement therapy.
Keywords: Heart failure, hypogonadism, testosterone deficiency, testosterone replacement therapy.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Volume: 13 Issue: 1
Author(s): Vito Angelo Giagulli, Edoardo Guastamacchia, Giovanni De Pergola, Massimo Iacoviello and Vincenzo Triggiani
Affiliation:
Keywords: Heart failure, hypogonadism, testosterone deficiency, testosterone replacement therapy.
Abstract: Testosterone deficiency syndrome (TDS) induces several negative effects that generally involve different organs such as testis, bone, skeletal muscle, and heart, leading to reduction in testis function, causing osteoporosis, strongly reducing muscle mass, decreasing exercise capacity and strength and facilitating heart failure. Approximately 25% of patients affected by chronic heart failure (CHF) is characterized by plasma Testosterone (T) levels below normal ranges also related to disease progression. In addition, reduction of circulating testosterone levels may contribute to some specific features of CHF, such as abnormal energy handling, weakness, dyspnoea and cachexia in particular. According to some recent evidence it has emerged that testosterone replacement therapy (TRT) may improve muscle strength and functional pulmonary capacity in CHF men with TDS.
This review will place emphasis on the pathophysiological role of testosterone deficiency in CHF men as well as the effects of the testosterone replacement therapy.
Export Options
About this article
Cite this article as:
Giagulli Vito Angelo, Guastamacchia Edoardo, Pergola Giovanni De, Iacoviello Massimo and Triggiani Vincenzo, Testosterone Deficiency in Male: A Risk Factor for Heart Failure, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/1871530311313010011
DOI https://dx.doi.org/10.2174/1871530311313010011 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small Artery Remodeling in Obesity and Insulin Resistance
Current Vascular Pharmacology Hyperglycemia and Diabetes Induced by Glucocorticoids in Nondiabetic and Diabetic Patients: Revision of Literature and Personal Considerations
Current Pharmaceutical Biotechnology Glibenclamide Action on Myocardial Function and Arrhythmia Incidence in the Healthy and Diabetic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Expression and Function of MicroRNAs in Heart Disease
Current Drug Targets Microenvironmental Regulation of Cancer Stem Cell Phenotypes
Current Stem Cell Research & Therapy Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy A Quantitative Structure-Activity Relationship Study on a Novel Series of Hydroxamic Acid Analogs Acting as Matrix Metalloproteinase Inhibitors
Letters in Drug Design & Discovery Polyploid Giant Cancer Cells (PGCCs): The Evil Roots of Cancer
Current Cancer Drug Targets MicroRNAs in the Diagnosis and Treatment of Unstable Angina
Current Topics in Medicinal Chemistry Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?
Current Vascular Pharmacology Editorial (Thematic Issue: Cell Metabolism and Current Challenges in Drug Research)
Current Pharmaceutical Design Polyphenols, Antioxidants and the Sympathetic Nervous System
Current Pharmaceutical Design Atrial Fibrillation and Ventricular Tachyarrhythmias: Advancements for Better Outcomes
Cardiovascular & Hematological Disorders-Drug Targets Management of Blood Pressure and Heart Rate in Acute Decompensated Heart Failure with Volume Overload
Current Pharmaceutical Design Cardiac Output by Flotrac/VigileoTM Validation Trials: Are there Reliable Conclusions?
Reviews on Recent Clinical Trials Progress in Imaging Agents of Cell Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Drug Delivery Design for Regenerative Medicine)
Current Pharmaceutical Design Drug Interactions between Non-Steroidal Anti-Inflammatory Drugs and Cardiovascular Treatments (Except Anti-Agregant Therapy)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Isolation, Structural Determination, and Evaluation of the Biological Activity of 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol [20(S)-25-OCH3-PPD], a Novel Natural Product from Panax notoginseng
Medicinal Chemistry Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Current Vascular Pharmacology